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Abstract: This perspective paper follows up on earlier communications on bacteriophage therapy
that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a
bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a
society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build on
the previously made recommendations and specifically address how the Nagoya Protocol might
impact the further development of bacteriophage therapy. By reviewing a number of recently
conducted case studies with bacteriophages involving patients with bacterial infections that could
no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and
significance of the development of international guidelines and frameworks that might facilitate the
legal and effective application of bacteriophage therapy by physicians and the receiving patients.
Additionally, we list and comment on several recently started and ongoing clinical studies, including
highly desired double-blind placebo-controlled randomized clinical trials. We conclude with an
outlook on how recently developed DNA editing technologies are expected to further control and
enhance the efficient application of bacteriophages.
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1. Introduction
The history of antimicrobial drug discovery includes more than 15 classes of compounds that
became a cornerstone in microbial infection control and management and have indisputably saved
many lives [1]. Indeed, they have become one of the most successful forms of therapy in clinical
medicine. This success, however, is compromised by the emergence and dissemination of antimicrobial
resistance, in part due to the widespread (over)use of these compounds in clinical and veterinary
medicine and agriculture, thus limiting the efficiency of antibiotics in the control and management
of infectious diseases [2]. The extent of the antimicrobial resistance problem in terms of increased
morbidity and mortality rates, as well as elevated healthcare costs, has been brought to the public’s
attention by several national and international health protection agencies, including the Centers for
Disease Control and Prevention (CDC), the World Health Organization (WHO), and the European
Medicines Agency (EMA) [3–5]. More specifically, WHO resolution 68.7.3 invites international, regional,
and national partners to implement the necessary actions in order to contribute to the accomplishment
of the five objectives of the global action plan on antimicrobial resistance. If no immediate action is
taken, the estimated death toll due to antimicrobial resistance will reach the millions by the year 2050,
the cost to the global economy is expected to rise to $100 trillion, and the number of people living in
extreme poverty is expected to increase [6].
In view of this alarming situation, we published a first opinion paper as a multidisciplinary
expert group on the acceptance and re-implementation of bacteriophage therapy in 2016 [7]. In this
present perspective paper, we briefly evaluate the status of the previously-made recommendations for
bacteriophage therapy over the short term. In addition, we comment on the consequence of the Nagoya
Protocol for bacteriophage therapy and then provide an overview on how limitations of the traditional
application of bacteriophage therapy could be overcome by the use of Clustered Regularly Interspaced
Short Palindromic Repeats/CRISPR associated systems (CRISPR/Cas) gene-edited bacteriophages in
the near future.
1.1. Factors Impacting the Broad-Scale Application of the Bacteriophages
Four issues have been identified that are limiting, or even preventing, the application of the
bacteriophage therapy in the Western World in the 21st century [7]: (1) Quality and quantity
of previously conducted study designs, (2) bacteriophage-cocktail production, composition, and
application methods in the context of the current legal framework, (3) Lack of awareness among
(para-) medical staff and the general public about the potential use of bacteriophage therapy, and
(4) Limitations in intellectual property protection for bacteriophage therapeutic applications.
1.1.1. Quality and Quantity of Previously Conducted Study Set-Ups
Bacteriophage therapy has been used for more than 100 years, mainly in Eastern Europe. However,
the number of double-blind, placebo-controlled, randomized clinical trials in different fields of
medical applications have been limited. Furthermore, they fall far from providing statistically-relevant
conclusions about the efficacy of bacteriophage therapy. As a consequence, health authorities and
medical professionals in the Western World have been hesitant to proceed with the bacteriophage
therapy. Table 1 provides an overview of recently concluded, or currently running clinical studies
with bacteriophages with excerpts from https://clinicaltrials.gov/. Notwithstanding the increase in
conducted trial numbers, the number of fully-completed and well-documented trials still remains too
low to draw substantial conclusions for the diverse range of medical applications where bacteriophage
therapy might be implemented. Of the completed trials, several factors have hampered their ability to
conclude on the potential efficacy of phage therapy.
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Small patient cohorts and the failure to recruit enough patients have severely limited the
conclusions that can be drawn from modern bacteriophage trials. For instance, the recently completed
Phagoburn trial, which represented a public investment of 3.85 million euro, enrolled a total of only
27 patients between 11 centers [8,9]. This was far from the pre-calculated 220 patients needed to
provide statistically significant results for the study. Reasons cited for the low number of participants
were restrictive patient inclusion criteria, a lower incidence of burn wound infections than in previous
years, and a shorter recruitment period due to regulatory constraints. Patient enrollment was limited
to mono-species infections at the request of the ethical committee, which does not represent the clinical
reality of burn-wound infections, and resulted in few eligible patients for the trial. Another trial using
bacteriophage for the treatment of pediatric Escherichia coli diarrhea also did not reach their estimated
patient numbers, because of early trial termination [10]. An in-depth failure analysis of this study
revealed that Streptococcus sp. may have been a better clinical target than as initially anticipated, E. coli.
These two studies, which represent the largest in recent history, highlight several lessons to be
learned for future bacteriophage therapy investigations. In addition to individual patient safety, ethical
committees should also consider the overarching purpose of clinical trials to produce significant and
generalizable results when reviewing clinical trial protocols; the inability to do so is both a detriment
to the well-being of society and a waste of trial-eligible patients. Priority should be given to infections
with established pathogens, and the test product should reflect the clinical reality to cover indicated
pathogens. There is no clinical evidence to suggest a safety concern for targeting multiple pathogens
with broad spectrum bacteriophage products, as supported by several recent clinical trials (Table 1),
the Polish experience, and the long-standing safe indication for commercial polyvalent bacteriophage
cocktails in Russia and Georgia [11–13]. Preliminary data from an ongoing trial on patients suffering
from urinary tract infections treated with a broad-spectrum bacteriophage cocktail in Georgia will
further assuage safety concerns [14]. Furthermore, in this Randomized Clinical Trials (RCT), one of
the inclusion criteria requires the in vitro sensitivity of the identified pathogen(s) to the bacteriophage
present in the cocktail, thereby acknowledging the very specific bacteriophage-bacterial host interaction.
In order to continuously enhance the spectrum of the cocktail during the study, resistant strains are
used for adaptation of Pyo bacteriophage cocktail [15].
Given the time and financial investment required for clinical trials, it might be prudent to exploit
information from smaller-scale clinical investigations, as well as the ongoing practice of bacteriophage
therapy in Eastern countries. Valuable knowledge to understanding bacteriophage therapy has already
been generated by The Polish bacteriophage Therapy Unit at the Hirszfeld Institute, a nonprofit entity,
that has accumulated data from years of individual patient reports [16]. Good insights can certainly be
derived from the several case reports that have provided more in-depth analysis of clinical samples
and clinical parameters, even compared to some of the more formal clinical trials. Furthermore,
bacteriophage therapy has been approved under emergency treatment schemes in the USA, Australia,
France, and Belgium. Table 2 summarizes a collection of recently reported case studies. A thorough and
objective assessment on the cost and benefits of bacteriophage production and therapy applications
in Russia, Georgia, and Poland, including production protocols, safety, and efficacy, would reveal
underlying strategies developed from decades of empirical bacteriophage use. Proper reporting should
be a priority for all uses of clinical bacteriophage therapy, whether it be formal trials or case reports [12].
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Table 1. Overview of bacteriophage therapy clinical studies.
Name of Study and
Organizations Running the Study Target Organism(s) Description and Objectives Outcome Measures Additional Comments
Clinical Trials.gov
Identifier/
Reference
Bacteriophages for treating urinary
tract infections in patients
undergoing transurethral resection
of the prostate: a randomized,
placebo-controlled, double-blind
clinical trial.
Tzulukidze National Center of
Urology, Tbilisi, Georgia; Eliava
Institute of Bacteriophages,
Microbiology, and Virology in
Tbilisi, Georgia; Balgrist University
Hospital, Zürich, Switzerland
The study is run in The Republic of
Georgia.
Enterococcus spp.,
Streptococcus spp.,
Escherichia coli,
Proteus spp.,
P. aeruginosa
Randomized placebo-controlled
double-blind clinical trial: Patients
planned for transurethral resection of
the prostate are screened for UTIs
and enrolled if eligible
microorganisms in urine culture are
≥104 cfu/mL.
Patients are randomized in a
double-blind fashion to the three
study treatment arms of 27 people,
each in a 1:1:1 ratio to receive either:
(a) bacteriophage (b) placebo
solution, or (c) antibiotic treatment
according to the antibiotic sensitivity
pattern.
Primary: Success of intravesical
treatment, defined as normalization of
urine culture (no evidence of bacteria,
i.e., <104 colony forming units/mL) after
7 days of treatment.
Secondary: Adverse events, in
categorization according to the National
Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE)
version four in grade one to five.
Tertiary: Changes in bladder and pain
diary assessment of number of voids,
number of leakages, post void residual.
The study uses the
commercially available
Pyo-bacteriophage
cocktail as produced by
The Eliava institute in
Tbilisi. 81 patients are
involved.
The Pyo-bacteriophage
cocktail is subjected to
continuous adaptation
during the study.
The study started in 2016,
and is expected to end in
2018.
NCT03140085 [14]
PHAGOPIED - Standard treatment
associated with bacteriophage
therapy vs. placebo for diabetic
foot ulcers infected by
Staphylococcus aureus.
The study is run by the Centre
Hospitalier Universitaire de Nı¯mes,
France, with collaboration with
Pherecydes Pharma, Romainville,
France.
Staphylococcus aureus,
MSSA and MRSA
This project utilizes
anti-Staphylococcus bacteriophages,
delivered topically, vs. a placebo
control.
The study uses random allocations in
a parallel assignment intervention
design.
The main objective of this study is to
compare the efficacy of standard
treatment associated with a topical
anti-staphylococcal bacteriophage
cocktail versus standard treatment
plus placebo for diabetic foot ulcers
mono-infected by
methicillin-resistant or susceptible S.
aureus (MRSA or MSSA) as measured
by the relative reduction in wound
surface area (%) at 12 weeks.
Primary: The relative reduction in
wound surface area over 12 weeks.
Secondary: Safety effects, local side
effects (rash onset or worsening of local
inflammatory signs) and general
symptoms (vital signs, fever, rash,
arthralgia, gastrointestinal symptoms).
First posted online in 2016.
This study is not yet
recruiting, but 60 patients
are expected to join.
NCT02664740
MUCOPHAGES - Bacteriophage
effects on Pseudomonas aeruginosa.
The study is run by the University
Hospital Montpellier, France.
Pseudomonas aeruginosa
The study is designed to evaluate the
efficacy of bacteriophages on P.
aeruginosa isolates recovered from
sputum.
The study utilizes a suspension of ten
bacteriophages. These are tested against
isolates recovered from cystic fibrosis
patients, to determine their ability to
infect these strains.
Completed in 2012.
No results posted online. NCT01818206 [17]
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Table 1. Cont.
Name of Study and
Organizations Running the Study Target Organism(s) Description and Objectives Outcome Measures Additional Comments
Clinical Trials.gov
Identifier/
Reference
Experimental bacteriophage
therapy of bacterial infections.
The study is led by the Polish
Academy of Sciences.
Staphylococcus,
Enterococcus, Pseudomonas,
Escherichia, Klebsiella,
Proteus, Citrobacter,
Acinetobacter, Serratia,
Morganella, Shigella,
Salmonella, Enterobacter,
Stenotrophomonas,
Burkholderia
The study uses suspensions of lytic
bacteriophages active against clinical
isolates of the test species.
The program determines to use
bacteriophage treatment in a
therapeutic role where no other
viable treatment is available.
For each patient only, specific
formulations of single bacteriophage
or a bacteriophage mixture that are
active against the pathogenic
bacterial strain or strains isolated
from the patient are used for the
treatment (oral, rectal and/or topical
application).
The principle focus of the work is to use
bacteriophage suspensions to treat the
following conditions: bone, upper
respiratory, genital and urinary tract
infections, as well as post-operative
non-healing wounds where antibiotic
treatment has not produced positive
results.
Start: 2005. Current status
unknown. Last update
posted in 2013.
Number of persons
involved has not been
stated.
NCT00945087 [11]
PhagoBurn. Phase I/II Clinical
Trial.
This Project is a European Research
& Development (R&D) Project
Funded by the European
Commission Under the 7th
Framework Program for Research
and Development Involving seven
Clinical Sites in France, Belgium &
Switzerland.
Escherichia coli &
Pseudomonas aeruginosa
Evaluation of bacteriophage therapy
for the treatment of Escherichia coli
and Pseudomonas aeruginosa wound
infections in burned patients
A randomized, parallel assignment
study assessing tolerance and efficacy
of local bacteriophage treatment of
wound infections due to E. coli or Ps.
aeruginosa in burned patients.
This study tests the efficacy of E. coli and
Ps. aeruginosa bacteriophage cocktails
against silver sulfadiazine to treat wound
infections by those bacterial species.
Primary: Time necessary for a persistent
bacteria reduction of two modes or
persistent bacteria eradication relative to
D0 adjusted on antibiotic treatment
(active on targeted strain) introduced
between D1 to D7.
Secondary: Assessment of tolerance of
treatment over 21 days. Adverse events
frequencies will be assessed in each
treatment arm. bacteriophage therapy
safety profile will be compared to safety
profile of standard of care.
Incidence and delay of infection
reduction with different bacterial species
from the targets over a period of
seven days.
Number of sites cured: The number of
infected burns or infected wounds
getting a clinical improvement will be
described and compared between
treatment group over a period of 7 day.
Launched in 2013 and
achieved in 2017,
PhagoBurn was the world
first prospective
multicentric, randomized,
single-blind and
controlled clinical trial of
bacteriophage therapy
ever performed according
to both Good
Manufacturing (GMP)
and Good Clinical
Practices (GCP).
Only 27 patients between
11 centers were included,
which is far from the
pre-calculated
220 patients needed to
provide statistically
significant results for the
study. See main text for
more information and
lessons learned.
NCT02116010 [8,9]
Antibiotics 2018, 7, 35 6 of 23
Table 1. Cont.
Name of Study and
Organizations Running the Study Target Organism(s) Description and Objectives Outcome Measures Additional Comments
Clinical Trials.gov
Identifier/
Reference
Antibacterial treatment against
diarrhea in oral rehydration
solution.
The study was run by Nestlé,
Switzerland in collaboration with
Dhaka Hospital of the International
Centre for Diarrheal Disease
Research, Bangladesh.
Escherichia. coli
(T4 bacteriophage)
This randomized double-blind,
placebo-controlled trial aims to
demonstrate the potentials of a new
form of therapy for childhood
diarrhea, by measuring the effect of
oral administered E. coli
bacteriophage in children aged
4–60 months of age with proven
ETEC and EPEC diarrha.
Primary outcome measures: Assessment
of safety, tolerability and efficacy (reduce
severity of diarrhea assessed by reduced
stool volume and stool frequency) of oral
administration of T4 bacteriophages in
young children with diarrhea due to
ETEC and/or EPEC infections. Time
frame: five days.
Secondary outcome measures: Clinical
assessment, blood tests, morbidity,
duration of hospitalization. Time frame:
five days.
First posted online 2009;
study ended in 2013.
Oral coliphages showed a
safe gut transit in children,
but failed to achieve
intestinal amplification
and to improve diarrhea
outcome, possibly due to
insufficient bacteriophage
coverage and too low E.
coli pathogen titers
requiring higher oral
bacteriophage doses.
NCT00937274 [10]
Existence in the human digestive
flora of bacteriophages able to
prevent the acquisition of
multiresistant Enterobacteria
(PHAGO-BMR).
The study is led by Assistance
Publique-Hôpitaux de Paris,
France.
MDR- Enterobacteria
The study plans to recruit 460 people
hospitalized in intensive care unit
(resuscitation). The choice of this unit
is linked to the fact that the
monitoring of resistant bacteria is
carried out regularly during the
hospitalization. On stool samples
collected at separate times of the stay
(admission and then during the stay),
the scientists look for 2 types of
bacteria and viruses capable of
destroying them.
Primary: Presence or absence of
bacteriophages capable of lysing
circulating Ec-ESBL/EPC or
Kp-ESBE/EPC in resuscitation units in
non-carriers having acquired carriers E.
coli or K. pneumoniae producing ESBL or
carbapenemases.
Secondary: Presence or absence of
bacteriophages in patients identified as
carriers of Ec-ESBL/EPC or
Kp-ESBL/EPC at entry to resuscitation
(control population).
Isolated bacteriophages will be
characterized.
First posted online in 2017.
The study is not yet
recruiting.
NCT03231267
Antibiotics 2018, 7, 35 7 of 23
Table 1. Cont.
Name of Study and
Organizations Running the Study Target Organism(s) Description and Objectives Outcome Measures Additional Comments
Clinical Trials.gov
Identifier/
Reference
METAKIDS Phages dynamics and
influences during human gut
microbiome establishment.
Enteric microbial species
This project relies on the ability of
Meta3C, a technique developed to
identify the bacterial host genomes of
the different bacteriophages the
investigators will detect thanks to the
physical collision these molecules
experience. Given the role that
human gut bacteriophages may play
in shaping the development of host
microbiomes, their potential for
application is of great interest.
Primary outcome measures: Genomic
reconstruction and characterization of
the different genomes (phages, bacteria,
yeast) present in the human gut during
the three first years of life. These
outcomes will provide a large catalog of
DNA sequences.
Characterization of the variation of the
different species present in human gut
during the three first years of life and
characterization of
bacteriophages-bacteria interactions.
This outcome will provide access to the
dynamics of the different species present
during this period and possibility to
correlate them with environmental
variation (dietary, age).
Secondary: Characterization of
bacteriophages and bacteria variations in
response to environmental perturbations
during infant gut development. Time
frame: two to three weeks.
First posted online in
2017; the study is
currently recruiting.
Estimated enrollment is
20 persons.
NCT03296631
Evaluate bacteriophage as a useful
immunogen in patients with
primary immune deficiency
diseases (PIDD)
The study is run by the University
of South Florida, USA.
Escherihia. coli
This protocol is designed to ascertain
whether the bacteriophage 0X174
neoantigen is safe and effective as an
antigen used in the evaluation of
primary and secondary immune
responses. Bacteriophage 0X174 is
given intravenously two billion
PFU/Kg of body weight; small blood
specimens of 3–5 mL (about
1 teaspoon) are collected after 15 min,
7 days, 14 days, and 28 days.
Primary Outcome Measures: Evidence of
capacity of switch from IgM to IgG
during 12 weeks of trial.
Blood samples are obtained after each
immunization of bacteriophages.
Current status unknown.
First posted online in 2012.
Last update 2012.
All patients receive two
doses of bacteriophages.
Selected patients may
receive a tertiary vaccine.
NCT01617122
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Table 1. Cont.
Name of Study and
Organizations Running the Study Target Organism(s) Description and Objectives Outcome Measures Additional Comments
Clinical Trials.gov
Identifier/
Reference
Evaluation and detection of facial
Propionibacterium acnes bacteria and
bacteriophage
The study is led by Maccabi
Healthcare Services, Israel.
Propionibacterium acnes
This multi-center, outpatient study
will extract and evaluate the presence
of facial P. acnes bacteria and
bacteriophage strains using pore
strips on up to 400 human subjects.
An additional P. acnes visual
detection method
(VISIOPOR®PP34N) will be used in
this study as per PI decision to
explore whether there is a correlation
between P. acnes bacterial presence
and fluorescent signal.
Primary: Detection and analysis of facial
P. acnes presence. Time frame: Day 0 and
week 8.
Secondary: Assessing correlation
between bacteriophage and P. acnes
using a. Demographic Questionnaire b.
Visual Supportive Methodology
(VISIOPOR®PP34N) as per PI decision.
Time frame: As above.
First posted online in 2017.
Not currently recruiting,
but 400 people are
estimated to participate.
NCT03009903
Bacteriophages PreforPro cocktails
as novel Prebiotics
The study is led by Colorado State
University, USA. PreforPro is
commercialized by Deerland
Enzymes,
Kennesaw, GA, USA
Enteric bacteria
The bacteriophage Study is a
randomized, double-blind,
placebo-controlled crossover trial
that investigates the utility of four
supplemental bacteriophage strains
(LH01-Myoviridae,
LL5-Siphoviridae, T4D-Myoviridae,
and LL12-Myoviridae) to modulate
the gut microbiota, and therefore
ameliorate common
inflammation-related GI distress
symptoms (e.g., gas, bloating,
diarrhea, constipation, etc.)
experienced by healthy individuals.
The main goal of this study is to see if
consumption of PreforPro, a
commercially available prebiotic
dietary supplement consisting of a
mixture of bacteriophages, improves
gut bacteria profiles in individuals
relative to a placebo control.
Primary: Microbiota modulation. Time
frame: Baseline visit prior to starting
treatments, four weeks after starting
treatment one, end of two-week washout
period, 4-weeks after starting treatment
two. Use of 16s rRNA sequencing of
stool samples to determine whether the
administered interventions resulted in
changes to microbial composition.
Secondary: Local inflammation Time
frame: as above. Inflammation in the
bowels will be assessed by use of ELISA
test for fecal calprotectin.
Systemic Inflammation. Time Frame:
As above. Systemic inflammation will be
assessed by an ELISA test for CRP and
circulating cytokines and immune
factors.
The study completed in
2017, but results have not
yet been posted online.
43 persons enrolled in the
study.
NCT03269617
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Table 1. Cont.
Name of Study and
Organizations Running the Study Target Organism(s) Description and Objectives Outcome Measures Additional Comments
Clinical Trials.gov
Identifier/
Reference
The Use of Bacteriophage Phi X174
to Assess the Immune Competence
of HIV-Infected Patients in vivo.
The study is run by the National
Institute of Allergy and Infectious
Diseases, USA.
Escherichia. coli
The objective of this study is to
evaluate the safety and utility of
bacteriophage phi X174
immunization as a tool to assess the
immune competence of HIV-infected
patients at different stages of disease
in vivo, and to assess the impact of
viral load levels and therapy-induced
changes in viral load levels on the
response to immunization with the
neo-antigen bacteriophage phi X174.
Primary. Immune parameters (not
further published online.
Study started in 1996, and
ended in 2000.
52 patients were involved
in the study.
NCT00001540 [18]
Randomized and double-blinded
placebo-controlled study of topical
application of AB-SA01 cocktail to
intact skin of healthy adults.
The study is run by AmpliPhi
bacteriophage Ltd., the US Army,
and the Walter Reed Army Institute
of Research Clinical Trials Center,
USA.
Staphylococcus aureus
The study aims to examine the safety
of ascending doses of AB-SA01 when
topically applied to intact skin of
healthy adults.
AB-SA01 consists of three
bacteriophages (viruses) that target
Staphylococcus aureus bacteria. The
safety of AB-SA01 will be assessed
when topically administered once
daily to the volar aspect of the
forearm at different doses for three
consecutive days.
Primary: Occurrence, intensity, and
relationship of adverse events (AEs)
from first dose through the end of study
visit (14 ± 2 days).
Change from baseline in clinical
laboratory tests. Time frame: Day 0
(pre-dose), Day 3, and Day 14 ± 2 days.
Clinical laboratory tests (hematology,
chemistry, and urinalysis).
Skin Reaction change from Baseline.
Time Frame.
First published online in
2016, and the last update
was in 2016 as well.
12 persons recruited.
NCT02757755
A prospective, randomized,
double-blind controlled study of
WPP-201 for the safety and efficacy
of treatment of venous leg ulcers.
The study was run by Southwest
Regional Wound Care Center, USA.
Pseudomonas aeruginosa
The study was designed to assess the
safety of Ps. aeruginosa-specific
bacteriophages for the treatment of
leg ulcers in human patients.
WPP-201 is a pH neutral, polyvalent
bacteriophage preparation, which
contains 8 bacteriophages lytic for
Ps. aeruginosa, S. aureus, and E. coli.
The cocktail contains a concentration
of approximately 1 × 109 PFU/mL of
each of the component monophages.
Primary: Evaluate the safety of the use of
WPP-201.
Study started in 2008 and
was completed in 2011.
64 patients were involved.
This study found no
safety concerns with the
bacteriophage treatment.
Efficacy of the preparation
will need to be evaluated
in a phase II efficacy
study.
NCT00663091 [19]
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Table 2. Human bacteriophage therapy related case studies published in peer-reviewed English-language scientific literature over the last ten years.
Case Study Title Description Outcomes Comments Reference
Refractory Pseudomonas
Bacteremia in a Two-Year-Old
sterilized by bacteriophage
therapy
The authors report a complex case that involved a pediatric
patient who experienced recalcitrant multidrug-resistant
Pseudomonas aeruginosa infection complicated by
bacteremia/sepsis; antibacterial options were limited because of
resistance, allergies, and suboptimal source control.
A cocktail of 2 bacteriophages targeting the
infectious organism introduced on 2 separate
occasions sterilized the bacteremia.
USA [20]
Development and use of
personalized
bacteriophage-based
therapeutic cocktails to treat a
patient with a disseminated
resistant Acinetobacter baumannii
infection
The authors report on a method used to produce a personalized
bacteriophage-based therapeutic treatment for a 68-year-old
diabetic patient with necrotizing pancreatitis complicated by an
MDR A. baumannii infection. Despite multiple antibiotic courses
and efforts at percutaneous drainage of a pancreatic pseudocyst,
the patient deteriorated over a 4-month period. In the absence of
effective antibiotics, two laboratories identified nine different
bacteriophages with lytic activity for an A. baumannii isolate from
the patient.
Administration of bacteriophages
intravenously and percutaneously into the
abscess cavities was associated with reversal of
the patient’s downward clinical trajectory,
clearance of the A. baumannii infection, and a
return to health.
USA [21]
Phage therapy in a 16-year-old
boy with Netherton syndrome
The authors report on a 16-year-old male with all the typical
manifestations of Netherton Syndrome, including atopic
diathesis and ongoing serious staphylococcal infections and
allergy to multiple antibiotics whose family sought help at the
Eliava bacteriophage Therapy Center when all other treatment
options were failing.
Treatment with several antistaphylococcal
bacteriophage preparations led to significant
improvement within seven days and very
substantial changes in his symptoms and
quality of life after treatment for six months,
including return visits to the Eliava
bacteriophage Therapy Center after three and
six months of ongoing use of bacteriophage at
home
Georgia. (Patient came
from France) [22]
Use of bacteriophages in the
treatment of
colistin-only-sensitive
Pseudomonas aeruginosa
septicaemia in a patient with
acute kidney injury—a case
report
A 61-year-old man with gangrene of the peripheral extremities,
resulting in the amputation of the lower limbs and the
development of large necrotic pressure sores, developed
septicaemia with colistin-only-sensitive P. aeruginosa. Intravenous
colistin therapy was started. Ten days later, the patient developed
acute kidney injury and antibiotic therapy was discontinued to
prevent further kidney damage. P. aeruginosa septicaemia
re-emerged and two bacteriophages, which showed in vitro
activity against the patient’s P. aeruginosa isolates, were
administered as a 6-h intravenous infusion for ten days.
Immediately upon bacteriophage application,
blood cultures turned negative, CRP levels
dropped and the fever disappeared. Kidney
function recovered after a few days.
Hemofiltration was avoided and no
unexpected adverse events, clinical
abnormalities or changes in laboratory test
results that could be related to the application
of bacteriophages were observed.
Belgium
The patient died four
months after
bacteriophage therapy
of sudden in-hospital
refractory cardiac arrest
due to blood
culture-confirmed
Klebsiella pneumoniae
sepsis.
[23]
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Table 2. Cont.
Case Study Title Description Outcomes Comments Reference
Bacteriophage treatment of
intransigent diabetic toe ulcers:
a case series
The authors present a compassionate-use case series of nine
patients with diabetes and poorly perfused toe ulcers containing
culture-proven Staphylococcus aureus infected bone and soft tissue,
who had responded poorly to recommended antibiotic therapy.
All infections responded to the bacteriophage
applications and the ulcers healed in an
average of seven weeks with infected bone
debridement. One ulcer, where vascularity was
extremely poor and bone was not removed to
preserve hallux function, required 18 weeks of
treatment.
USA [24]
Use of bacteriophages in the
treatment of Pseudomonas
aeruginosa infections
The author reports on bacteriophage treatment of Pseudomonas
aeruginosa otitis in a pet dog and in a human burn wound patient.
Symptomatic improvement and bacteriophage
multiplication were seen in the pet dog and in
the human patient.
UK [25]
Clinical aspects of
bacteriophage therapy
The authors present a detailed retrospective analysis of the
results of bacteriophage therapy of 153 patients with a wide
range of infections resistant to antibiotic therapy admitted for
treatment at the bacteriophage therapy unit of the Ludwik
Hirszfeld Institute of Immunology and Experimental Therapy,
Wrocław, Poland, between January 2008 and December 2010.
Data suggest that bacteriophage therapy
provided good clinical results in a significant
cohort of patients with otherwise untreatable
chronic bacterial infections and is essentially
well tolerated.
Poland [11]
Bacteriophage therapy for
refractory Pseudomonas
aeruginosa urinary tract infection
The authors describe adjunctive bacteriophage therapy for
refractory Pseudomonas aeruginosa urinary tract infection in the
context of bilateral ureteric stents and bladder ulceration, after
repeated failure of antibiotics alone.
Combined therapy was well-tolerated,
apparently resulting in symptomatic relief and
microbiological cure where repeated courses of
antibiotics combined with stent removal had
failed. Bacteriophage did not persist nor was
any antibiotic- or bacteriophage resistant P.
aeruginosa identified.
Australia
Additive effort of
combined
bacteriophage-antibiotic
treatment
[26]
Eradication of Enterococcus
faecalis by bacteriophage
therapy in chronic bacterial
prostatitis
The authors report on the treatment of three patients suffering
from chronic bacterial prostatitis who were qualified for an
experimental bacteriophage therapy protocol managed at the
bacteriophage Therapy Unit in Wrocław. The patients had
previously been treated unsuccessfully with long-term targeted
antibiotics, autovaccines, and laser biostimulation.
Rectal application of bacteriophage lysates
targeted against Enterococcus faecalis cultured
from the prostatic fluid gave encouraging
results regarding bacterial eradication,
abatement of clinical symptoms of prostatitis,
and lack of early disease recurrence.
Poland [27]
Corneal Infection Therapy with
Topical Bacteriophage
Administration
A 65-year-old woman suffering from MDR S. aureus infection of
the cornea as a post-operative complication of a craniotomy. This
patient suffered the chronic, persistent infection for years before
seeking therapy in Tbilisi, Georgia. A single bacteriophage was
administered both topically in the eye and nasal application and
intravenous application for four weeks.
The patient’s regular physicians published that
the patient’s ocular and nasal cultures after
returning from Georgia were negative at three
and six months post-treatment.
Georgia. (Patient came
from France) [28]
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Table 2. Cont.
Case Study Title Description Outcomes Comments Reference
The use of a novel
biodegradable preparation
capable of the sustained release
of bacteriophages and
ciprofloxacin, in the complex
treatment of multi-drug
resistant Staphylococcus
Aureus-infected local radiation
injuries caused by exposure to
Sr90.
Authors report the topical use of PhagoBioDerm (phage +
ciprofloxacin wound polymer) to treat two wounds infected with
S. aureus after the failure of conventional treatment. The
responsible pathogen was resistant to ciprofloxacin, but sensitive
to the bacteriophage.
PhagobioDerm resulted in reduced purulent
drainage and symptom amelioration. S. aureus
was eliminated from the wound
Georgia [29]
Successful eradication of
methicillin-resistant
Staphylococcus aureus (MRSA)
intestinal carrier status in a
healthcare worker
Healthcare worker suffered urinary tract infections caused by
MRSA that was carried in the GI tract. Authors report that
bacteriophage was applied orally
Eradiation of carrier status Poland [30]
Phage therapy compassionate
use in France in 2017.
Abstract presented by Pherecydes at bacteriophages-sur-Yvette in
November 2017 documenting the use of bacteriophage to treat
two patients with severe bone and joint infections caused by
MDR organisms with topical bacteriophage at a hospital in Lyon.
Symptom amelioration and no reported side
effects. France [31]
Open-label treatment of RCT
with bacteriophages for treating
urinary tract infections in
patients undergoing
transurethral resection of the
prostate: a randomized, as
mentioned in Table 1.
Prior to the start of the double-blind placebo-controlled trial, nine
patients were treated with bacteriophage Pyo cocktail.
In six of nine patients, the titer of the
pathogenic bacteria was decreased, varying
between 1 log and 7 log (sterile).
Georgia NCT03140085[14].
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1.1.2. Bacteriophage Production and Application Methods in Context of the Current Legal Framework
Today’s legislation and safety requirements for the production and admission of drugs are,
for good reasons, heavily controlled. By having strict quality control procedures, it is assured that
drugs are effective, safe, and produced with a consistent quality and composition. The production
and application of bacteriophage therapy should not be any different. However, the nature of
bacteriophages and their effective medical application are not compatible with current production and
admission requirements for chemical drugs. The intrinsic strength of bacteriophages relates to their
antagonistic evolution with their bacterial hosts. To assure an effective application of bacteriophage
therapy, this requires the ability to continuously adjust and adapt the composition of bacteriophage
cocktails. Such a flexible and dynamic production system, coupled with the application of an
infection-eliminating medication is incompatible with current legislation and safety requirements
set for traditional static and chemically produced drugs. Although the use of bacteriophages is
already quite old, in fact, their tailor-made use and applications are in line with the growing demand
and insights around personalized nutrition and personalized medicine, where DNA, microbiome
composition, and personal lifestyle act as leading indicators.
Previously, we referred to a couple of proposals to overcome this incompatibility with today’s
regulatory frameworks in the Western World, while still assuring safety and efficacy [7]. For instance,
the creation of a new EC Directive in Europe concerning bacteriophages and bacteriophage cocktails
for human use, or an update of the already existing Medicinal Products Directive 2001/83/EC with a
specific amendment for bacteriophages and bacteriophage cocktails, or to register bacteriophages and
bacteriophage cocktails under the Council Directive concerning medical devices (93/42/EEC) [32].
A recent breakthrough in this debate has occurred in Belgium, where the national authorities agreed
on implementing a pragmatic phage therapy framework that centres on the magistral preparation
(compounding pharmacy in the US) of tailor-made phage medicines [33]. There is good reason to
believe that this Belgian “magistral phage medicine” framework will be flexible enough to exploit
and further explore the specific nature of bacteriophages as co-evolving antibacterials whilst giving
precedence to patient safety.
Regarding good manufacturing practices, experts are in agreement that these should be defined
in the specific context of bacteriophages as natural entities. The use of whole genome sequencing
technologies, together with several additional specific controls [7], can assure the safety of newly
identified or adapted bacteriophages and bacteriophage products in general. Rapid sequencing will
also allow the safe incorporation of the unique feature of bacteriophage therapy that when in the case
of acute infections, new bacteriophages can be isolated within 48 h, or adapted to counteract potential
resistance of emerging pathogens. Quality and safety requirements for bacteriophage therapy products
have been listed in Table 1 in the previously published paper [7].
Another suggested mechanism that was highlighted by the panel members to ensure the safety
of bacteriophage therapy relates to the implementation of a monitoring system. This would function
much like that for antibiotic resistance, and should be put into place as soon as bacteriophage therapy
has started. The main purpose of the monitoring system is to collect data for prospective analyses, as
well as to detect and follow the development of bacterial resistance to bacteriophages.
Several researchers have made proposals for the safe re-implementation of bacteriophages by
establishing validated bacteriophage collections in hospitals for compassionate use applications.
In this way, as soon as the bacterial pathogen has been identified, which is often practiced already,
it could be tested for sensitivity against such a library of bacteriophages [34]. Another suggestion
refers to installing dedicated public structures, National Reference Centres for bacteriophage therapy,
that can conduct pilot treatments and facilitate production of hospital-based bacteriophage solutions,
and application protocols that will ensure adequate product quality, patient safety and monitoring
of treatment efficacy [35]. Such a way of working is, in fact, already operational at the bacteriophage
therapy centre located at the Hirszfeld Institute of Immunology and Experimental Therapy in Wroclaw,
Poland [16].
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1.1.3. Lack of Awareness among (Para-) Medical Staff and the Public About Bacteriophage Therapy
For many years, the history and potential of bacteriophage therapy was out of sight for people
in the Western World, including medical staff and patients. Following the international increase of
antibiotic resistance of pathogens and since the 100th anniversary of bacteriophage therapy in 2017,
there has been a clear increase in reporting and communication on bacteriophage therapy in all forms
of media in many Western countries, including scientific opinion articles, television programs, and
social media initiatives. Also, the increase of medical tourism to Georgia or Poland for bacteriophage
treatment illustrates a growing awareness on and demand for bacteriophage therapy.
Despite this increase of public awareness, panel members feel that there is still not enough
interface with the medical community. Little focus is given in the curricula used for (para-) medical
trainees on phage therapy, including bacteria-phage antagonistic evolution. Expertise on phage therapy
could easily be provided through researchers who by reaching out to their medical colleagues operating
at local hospitals. In this way, relevant information can be disseminated about the pros and cons
of bacteriophage therapy in the context of the emergence and spreading of antimicrobial resistance.
The increased awareness could thus lead to more application of bacteriophages for compassionate
use as described above. At the same time, hospitals and patients should be aware that bacteriophage
therapy will not always be successful and yet unknown safety risks and complications cannot
be excluded.
1.1.4. Limitations in Intellectual Property Protection
Bacteriophages are ubiquitous natural organisms that are relatively easy to isolate from the
environment and have been in the public domain since the 1920s, and therefore the possibilities
for intellectual property (IP) protection are limited. Although this might be seen as a limitation by
companies intending to seriously invest in bacteriophage therapy, in fact it also offers the opportunity
for local, national, and supra-national state-supported medical care to collectively invest in the
development of bacteriophage therapy that is expected to be more cost-effective for treatment of
many infectious diseases compared to several of the currently used antibiotics. The expected efficacy
and affordability of bacteriophage therapy is also illustrated by initiatives around development of
bacteriophage therapy in developing countries. In these situations, people are disproportionately
impacted by infectious diseases, leading to a critical disease burden on healthcare budgets, and where
standard medical care is already difficult to afford for the majority of the population [36].
We expect IP protection opportunities to exist for bacteriophage production methods, as well
as for applications that can enhance the efficiency and quality of bacteriophage therapy, and/or
improve shelf-life stability. Opportunities to protect IP will also come from genetically-engineered
bacteriophages, as outlined further in this article. In addition, we see options for private/government
partnerships with patent pools under supra national governance that should be managed through
organizations such as the WHO, CDC, ECDC or UN [37].
2. The Nagoya Protocol and the Implications on Bacteriophage Therapy
In order to increase acceptance and implementation of bacteriophage therapy, it is obvious that
rapid and efficient procurement of bacteriophages from the environment with therapeutic potential,
and their bacterial hosts, is essential. Bacteriophages, along with all other genetic (biological) resources,
are regulated by the Nagoya Protocol (NP). Briefly put, this means that regulations governing the
collection of bioresources from natural environments and subsequent benefit-sharing with the country
of origin are increasingly important (Box 1).
In 2017, several authors evaluated the impact of the NP on research and international cooperation,
the need for best practices for benefit-sharing, and proposed adjustments to the NP to accommodate
microbiological research and development (R&D) [2–4]. Since microorganisms are typically ubiquitous
and of the same constitution across the world, it was argued that the expectations of the NP as set
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by lawmakers is scientifically unfeasible. Similar to their bacterial hosts, bacteriophages are also
cosmopolitan, and an estimated 107 bacteriophage particles might be present in any one milliliter
of natural sample. As a result, thousands of new genetic resources can result from a single step of
sampling from the environment, but there are thousands of diverse natural environments around the
world that are not limited to one specific country or region of interest. New environmental samples
are themselves inherently worthless, as the potential for each bacteriophages and bacterial isolates is
unknown and intensive research is necessary to purify and evaluate these characteristics. Additionally,
high numbers of specific bacterial hosts are required for phage amplification, to determine the activity
spectrum, and to increase their efficacy in clinical applications. Taken together, these scientific realities
mean that researchers will be likely to search for bacteriophages/hosts where NP restrictions are either
not in place, or where the NP highly efficiently organized.
Bacteriophages offer great potential for human and veterinary medicine, but NP regulations could
be interpreted as in conflict with the WHO objective (and subsequent G7 and G20 summits) calling for
all countries to develop alternative antibacterial strategies in human medicine [38]. Also in the case of
serious outbreaks of foodborne infections, requiring urgent response, (e.g., Germany in 2011 with the
outbreak of E. coli O104:H4 EAHEC that caused more than 50 cases of deaths), the NP might impede
progress in the global search for potent therapeutics and straightforward exchange of bacteriophages
that could save lives.
For microorganisms in general, and for research and applications of bacteriophages in particular,
we share the concerns put forward in the Lactic Acid Bacterial Industrial Platform (LABIP) [39] and
Microbiological Research Under the Nagoya Protocol: Facts and Fiction [40] and would welcome the
following amendments to the NP: 1. Precise definitions of terms like “utilization” and “research
and development”, so there is regulatory certainty about what is meant when these words are
written in the Nagoya Protocol; 2. Guidelines to consider R&D expenditure around bacteriophages
and related investment for basic microbiological research in the terms of agreement on benefit
sharing, 3. Simplification of the NP requirements in case of screening activities of a large number
of bacteriophages and potential host strains aimed to find a just few candidates with specific
characteristics; 4. Research using digital sequence information of bacteriophages and host strains
to remain outside the scope of the NP and ABS legislations, as it would be a daunting task to
obtain PIC and MAT for all relevant sequences in a database such as GenBank. 5. In case of
infection outbreaks, rapid exchange of material should be uncomplicated and governed by a generic
international benefit-sharing agreement that is ready for the unexpected.
Box 1. Explanation about the Nagoya Protocol.
The NP is a new international regime that came into effect on 12 October 2014, and has been ratified by more than
100 countries. The NP is the implementing treaty for the Convention on Biological Diversity (CBD, www.cbd.int), which
itself has been in force since December 1993, and is intended to harmonize access and benefit-sharing mechanisms for the
retrieval of biological resources out of provider countries (often in emerging economies). The purpose of the NP is to achieve
the objectives of the CBD: 1. Conservation of biodiversity, 2. Sustainable use of the genetic resources and 3. Balanced and
equitable sharing of benefits when genetic resources are used (Access and Benefit Sharing (ABS)). Hereto, before starting any
research and development work on biological resources, Prior Informed Consent (PIC) by the ‘provider country’ is needed,
which done according to Mutually Agreed Terms (MAT) to be laid down in a contract describing access to the materials and
how benefits will be shared. In practice, benefit sharing can take a variety of forms, including monetary payments, for example
with royalties or research funding, but also via non-monetary forms, such as technology transfer or scientific collaborations.
Historically, bioresources were considered a shared heritage of humankind, and the NP allows signatories to regulate access to
genetic resources to ensure benefit-sharing with such provider country. Generic guidance flowcharts are given by Overmann
and Scholz [40] and Smith et al. [41].
Within the EU, member states are varied in the regulation of access to genetic resources, with northern Member States often
allowing unrestricted access and southern States considering regulation. The United States neither ratified the CBD nor the NP,
but these international agreements do affect U.S. scientists and aligned standard operating procedures are in development [42].
The primary resource for determining whether there are restrictions imposed on a genetic resource is the ABS Clearing-House
(ABSCH) (https://absch.cbd.int/), which provides country profiles and, if appropriate, national regulations that, ideally,
explain how to access their sovereign genetic resources, including required documents such as PIC and MAT. Due to the
current lack of completed country profiles in the ABSCH, it is often difficult to find the practical information needed to be
compliant with the NP. The long-term implications for phage research are unclear, but conceivably threatened.
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3. The Future of Bacteriophage Therapy by the CRISPR/Cas System
In the era of gene editing, it is relevant to study the potential of genetically-modified
bacteriophages as therapeutics. Bacteriophages could be engineered for better efficacy and a broader
range of application, and, importantly, would be more attractive for investors due the generation of
IP rights (see above). Recent advances in CRISPR/Cas-editing (see Box 2) made bacteriophage DNA
editing a hot-topic, since this method can be applied on basically every bacteriophage regardless of its
size, host, or properties. Even bacteriophages encoding anti-CRISPR proteins or bacteriophages
without a mechanism for repairing CRISPR/Cas-induced breaks can be edited using different
CRISPR/Cas types, or by incorporating a repairing protein from another bacteriophage in trans [43].
The strategies based on therapeutic genetically-engineered bacteriophage, which we mentioned
previously [7], were constructed almost exclusively for E. coli, due to the range of editing strategies
already developed for this model bacterium. On the contrary, CRISPR/Cas-editing can be applied
also to bacteriophages targeting members of the ESKAPE pathogen group (Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter species). This has already been proven in Staphylococcus aureus and bacteriophage ISP [44],
which is member of the same genus Kayvirus as a bacteriophage used in the EU-approved therapeutic
STAFAL®. Thus, previously proposed applications of genetically-engineered bacteriophages are
expected to get relevant clinical significance as summarized in Table 3.
Seven bacteriophages from various hosts have recently been successfully edited using three
different types of CRISPR/Cas (Table 4): i. type I-E, prevalent in E. coli, ii. type II-A, which requires
only one protein Cas 9 and sgRNA for editing ability and is best described so far, and iii. type III-A,
which does not require a protospacer adjacent motive and cannot be evaded by simple nucleotide
substitution [44].
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Table 3. Targets for genetic engineering for bacteriophage therapy applications.
Gene Modification Purpose Advantage to Natural Bacteriophage Therapy Related Reference
Antimicrobial protein * Insertion/gene replacement Phage killing other strains Product for mixed infections
[7]Biofilm degrading enzyme * Insertion/gene replacement Degrading biofilm More active against biofilm-producing strains
Virulence factor Gene deletion No virulence transfer Novel therapeutic bacteriophage
Baseplate proteins/tail fibers Gene replacement Altered host-range Novel therapeutic bacteriophage for mixed infections
Receptor-binding
protein/structural proteins Single gene mutations Broader host-range
More effective, and faster to obtain than by natural
selection [45]
Major capsid protein Purification tags insertion More efficient purification Purer product [46]
Major capsid protein Anti-immune tagsinsertion/single gene mutations Longer circulation in bloodstream
More effective, and faster to obtain than by natural
selection [47]
Various, e.g., lytic module Gene knockout Non-replicative bacteriophage Replication control of a bacteriophage [48]
Endotoxin antibody * Insertion/gene replacement Endotoxin removal Safer product [49]
* Foreign genes.
Table 4. Summary of Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR associated systems (CRISPR/Cas) applications in the editing
of bacteriophages.
Bacteriophage Host CRISPR/Cas TypeEmployed Mutation Purpose Gene Reference
T7 E. coli I-E Gene deletion PoC of CRISPR/Cas-editing inbacteriophage gene 1.7 [43]
2972 Streptococcus thermophilus II-A/Cas9 Gene replacement withmethyltransferase/Gene deletion
PoC of native II-A editing,
bacteriophage resistant to RM system orf 33, 39 [50]
ICP1 Vibrio cholera I-E Gene deletion/Gene replacement with GFP PoC in Vibrio model cas 1, cas 2–3 [51]
P2 Lactococcus lactis II-A/Cas9 Deletion/insertion/substitution PoC of heterologous II-A editing orf 24, 42, 47, 49 [52]
T4 E. coli II-A/Cas9 Substitutions, deletion PoC of editing by two gRNA,functional study of gene knock-out mcp, rnlB [53]
Andhra Staphylococcus epidermidis III-A/Cas10 Substitutions PoC of native III-A editing orf 9, 10 [44]
ISP Staphylococcus aureus III-A/Cas10 Substitutions PoC of heterologous III-A editing orf 61 [44]
PoC—proof-of-concept, RM—restriction modification.
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Box 2. CRISPR/Cas editing.
CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR associated systems) was
originally identified as a prokaryotic adaptive immune system. It mediates the cleavage of foreign DNA by
Cas nuclease if this DNA matches the sequence of spacers in the CRISPR locus. It soon became an important
method for eukaryotic genome engineering. However, a limited number of studies have been concerned with its
application in bacterial genome engineering due to the poor ability of bacteria to repair CRISPR/Cas-induced
breaks [54]. Bacteriophages, on the other hand, have evolved several mechanisms to repair such breaks, as a way
to increase the probability of escaping the bacterial immune system. Bacteriophages thus represent an excellent
model for optimizing CRISPR/Cas as a prokaryotic genome engineering tool, as well as for various practical
applications of modified bacteriophages (for review see Bardy et al. 2016, [55]).
4. Limitations and Concerns for CRISPR/Cas Gene Edited Bacteriophages
4.1. Efficacy
One of the unknowns concerning CRISPR/Cas-edited bacteriophages relates to whether the
mutations will be preserved and reproduced, or if spontaneous mutants that escape the CRISPR/Cas
will arise and, due to increased fitness, will outgrow the recombinant. As a consequence,
bacteriophages with many point mutations in inserted foreign genes and tags would emerge, rendering
the intended modifications useless. A solution could potentially come through the application of
CRISPR/Cas III-A, where there has been no evidence of escape mutants [44]. However, in order to
understand the long-term effect of CRISPR/Cas-based selections on the bacteriophage population,
more research is necessary. In CRISPR/Cas II-A type, it is possible to utilize several spacers targeting
different locations in the gene of interest, which will reduce the probability of escape. This technique,
however, becomes more laborious with every additional step and might still prove to be non-efficient.
4.2. Legislative Hurdles
CRISPR/Cas-edited bacteriophages with heterologous gene insertions would rank as genetically
modified organisms (GMOs), which brings additional hurdles to their approval as therapeutic agents.
Their future success will therefore depend on the safety and environmental regulation of GMOs in
individual countries. At present, the United States and China appear to have far more amenable
policies and prospects for GMO acceptance compared to the EU and Russia. The reproducibility
and viability of a genetically modified bacteriophage could also be eliminated by introducing lethal
mutations to ensure that the modified bacteriophage would disappear over time, therefore decreasing
environmental concerns. Another option is to transform the bacteriophage to a non-replicative delivery
vehicle that would mediate killing by an alternative approach (Box 3), which is currently becoming an
important focus of research interest in terms of modified bacteriophage therapy. The production of such
bacteriophages would require the use of a modified host strain, or presence of a helper bacteriophage to
facilitate reproduction. For such applications, the efficacy of such modified constructs in bacteriophage
therapy remains to be investigated.
Box 3. CRISPR/Cas-based antibiotics delivered by bacteriophage.
Apart from editing, CRISPR/Cas has been utilized as a weapon for the specific killing of virulent or
antibiotic-resistant bacterial strains, by reprogramming CRISPR/Cas to target a gene sequence encoding such
a property. A bacteriophage can serve as a delivery vehicle, by binding to the relevant bacterial strain and
transferring DNA encoding Cas9 nuclease and sgRNA into the cell. This DNA is packaged into the bacteriophage
capsids by introduction of specific bacteriophage packaging sites on both ends of the sequence. As a result, only
the targeted strain is eliminated, therefore preserving the rest of the microbiome. In addition, the transfer of the
undesired phenotypic traits is abolished among strains infected by the delivery bacteriophage. Many groups
are studying this strategy (for review see Fagen et al. 2017 [48]), with several start-ups (Locus in US, Nemesis
in UK or Eligo in France) already developing such a bacteriophage for commercial use. Still, classic problems
of bacteriophage therapy, such as finding suitable bacteriophages for each individual pathogenic strain or the
potential immune reaction of the body to large doses of bacteriophage virions, remain obstacles for application.
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4.3. Safety and Environmental Risks
Despite the absence of adverse reports and also the recent progress and resulting knowledge in
the area of natural bacteriophage immunogenicity [16], the mechanism of bacteriophage tolerance by
the human immune system is not yet entirely understood. Since bacteriophages need to be applied in
a relatively large amount or can replicate at the site of the bacterial infection to high titers, their effect
on the human immune system requires thorough investigation. Furthermore, especially in the area
of GM bacteriophages, there might be unique health and safety risks that require careful evaluation,
such as the possible side effects around the application of long-circulating bacteriophages (Table 3).
Also, bacteriophages with modified structural proteins, displaying purification tags, or with additional
receptor-binding domains may represent novel antigens for the immune system. In the case of using
bacteriophages as delivery vehicles, even in the non-lytic killing strategy, cells could be lysed by
the patient’s immune system and the cell content containing modified proteins or endotoxins thus
released into the bloodstream. The (in) stability of modified bacteriophages and the consequences of
spontaneous mutations are other safety targets that require investigation.
Given the continuous need for propagating host strains, the probability of survival of
bacteriophages, including modified bacteriophages, outside the laboratory or hospital is minimal.
However, the risk of recombination between modified and wild-type bacteriophages or horizontal
gene transfer among modified bacteriophages and bacteria must be evaluated, particularly in
case bacteriophages would carry genes foreign antibacterial products. Theoretically, uptake and
incorporation of such sequences by a bacterium may result in a fitness advantage over the strain for
which the bacteriophage was originally designed.
5. Discussion and Conclusions
The urgent need for effective alternatives to antimicrobials is self-evident in order to reduce the
morbidity and mortality associated with antimicrobial resistance, as well as reducing the healthcare
burden on economies. Many proposals have been made on which path bacteriophage therapy should
follow in order to be approved. A recurrent conclusion is that this therapy will never become a viable
option if we continue assessing this treatment under the same regulatory frameworks as for chemical
drugs. In fact, bacteriophage therapy is already safely being applied today, as demonstrated not
only from ongoing activities in Eastern Europe, but also from the observation that already for more
than a decade several of the successful bacteriophage therapy cases reported in the Western World
(Table 2) are led by military hospitals who have the flexibility to invest in therapies which are not yet
legally approved.
If bacteriophage therapy is to develop as a means to stop the emergence of antibiotic resistance,
courageous decision making is needed that allows the controlled use of bacteriophage. This needs
to take into consideration the many years of practice in Russia, Georgia and Poland, and which is in
line with many good proposals from scientists and physicians who understand the specific nature
of bacteriophages.
At the same time, we should not expect that bacteriophage therapy will always be 100% effective
and might occasionally induce side effects, as we will understand better upon the implementation
of bacteriophage therapy monitoring systems. But how does the occurrence of potential side
effect compare to the opportunity costs of not applying bacteriophage therapy in case of antibiotic
resistance? Furthermore, also for antibiotics that in many cases are lifesaving, we accept undesired side
effects, for instance when due to the unspecific mode of action of antibiotics beneficial microbes
are also affected, which often causes complications such as antibiotic-induced dysbiosis and
secondary infections.
A great step forward can be made when more countries will follow the example of the Belgian
Ministry of Public Health regarding the set- up of a phage therapy framework that centers on
the magistral preparation (compounding pharmacy in the US) of tailor-made phage medicines.
Importantly, this Belgian solution assures safety and avoids the application of certain medicinal
Antibiotics 2018, 7, 35 20 of 23
product requirements that restrain flexible phage therapy approaches, such as compliance to Good
Manufacturing Practice [33].
In this paper, we have underlined the call for more RCTs with bacteriophage therapy. In this
context, it is also an important responsibility of the researchers involved to properly report the outcome
of the studies, as has not always been the case (Table 1). Incomplete reporting on clinical studies
does not help to gain confidence on pros and cons of new therapies. Besides the mentioned need
for more studies, at the same time we reason that depending on the type of infection, a traditional
RCT might not always be the most efficient route to determining bacteriophage efficacy, and it is not
only bacteriophage therapy that finds itself in this predicament. An increase in personalized-medicine
approaches, particularly for cancer treatments, have necessitated different designs for clinical trials [56].
N-of-1 studies, where a patient is the entire study, has become increasingly frequent to evaluate
treatments for rare diseases or pain reducers. Basket designs permit the selection of patients with
molecular markers that make them likely to respond to a certain treatment; this is not unlike pre-testing
bacterial isolates for bacteriophage sensitivity prior to trial enrollment. The increasing frequency of
case-reports for bacteriophage therapy suggests that bacteriophage therapy may be heading in the
direction of a personalized treatment, at least for some diseases (Table 2).
With regard to the Nagoya Protocol, we call for pragmatic approaches to obtain Prior Informed
Consent (PIC) and Mutually Agreed Terms (MAT) that are proportional to the value of the immediate
foreseen benefits. Otherwise, due to the delays that might be encountered in the process, there may
not be any significant benefit to share. Since there are, at present, very few culture collections with
bacteriophage holdings, new bacteriophages have to be isolated in high numbers to constantly fulfill the
WHO resolution 68.7.3 (WHO Assembly October 2016). The proposed amendments and clarifications
to NP as mentioned in the section on NP could facilitate that the protocol does not unintendedly retard
these innovative developments that are important for humankind in the 21st century. This is especially
valid for a rapid and effective application of bacteriophages in the events of emergency since users
should ensure legally-complied uses of the genetic resources, including those for collaborative projects.
While it becomes increasingly acknowledged that bacteriophage therapy, as applied already for
many years in some countries, has great potential to combat the consequences of increasing antibiotic
resistance, we acknowledge that the traditional bacteriophage therapy also has some limitations.
In this article, we have described that the use of CRISPR/Cas to specifically edit the genome of natural
bacteriophages offers an opportunity for controlled and effective bacteriophage therapy and may
facilitate reliable future applications of the bacteriophage therapy. However, today several technical
issues and safety concerns of GM bacteriophages still need to be addressed. The first step would
be to prove that modified bacteriophages could be prepared in large-scale, without any significant
background of undesirable mutants. Next, research should focus on immunogenicity assessment of
modified virions and potential horizontal transfer of genes encoding antibacterial products. We expect
that in a time frame of five-to-ten years, it will become clear if this approach for bacteriophage therapy
is worthwhile. Furthermore, it is foreseen that CRISPR/Cas-edited bacteriophages will revolutionize
bacteriophage therapy, if not by direct application of modified bacteriophages, by the enormous
possibilities that it will bring to fundamental research on bacteriophage biology.
Although the entire world seems to agree on the clear urgency to implement novel solutions, it is
worrying to see that therapy with natural bacteriophages has yet to be seriously considered in the
Western World. Notwithstanding some open questions, there are many realistic options and scenarios
that would enable a gradual, pragmatic, and responsible re-implementation of bacteriophage therapy
in the short term to help avoid needless deaths due to antibiotic-resistant infections. Any further delay
could be seen as a supported prolongation of the difficult conditions many patients without alternative
treatment options find themselves in today.
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